Latest news with #GodavariBiorefineries
Business Standard
08-08-2025
- Business
- Business Standard
Godavari Biorefineries reports consolidated net loss of Rs 16.02 crore in the June 2025 quarter
Sales rise 2.05% to Rs 533.24 croreNet Loss of Godavari Biorefineries reported to Rs 16.02 crore in the quarter ended June 2025 as against net loss of Rs 26.11 crore during the previous quarter ended June 2024. Sales rose 2.05% to Rs 533.24 crore in the quarter ended June 2025 as against Rs 522.53 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% 2 OPM %1.08-2.34 -PBDT-8.80-29.06 70 PBT-22.30-41.64 46 NP-16.02-26.11 39 Powered by Capital Market - Live News
&w=3840&q=100)
Business Standard
22-07-2025
- Business
- Business Standard
Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug
Godavari Biorefineries share price today: Shares of Godavari Biorefineries surged 5 per cent on Tuesday, July 22, 2025, recording an intraday high of ₹327.43 per share. At 01:35 PM, shares of Godavari Biorefineries were trading at the day's highest level on the National Stock Exchange. In comparison, NSE Nifty was trading largely flat at 25,082.45, down by 8 points. The total market capitalisation of the company stood at ₹1,675.66 crore. So far this calendar year, the shares of the company have remained flat, albeit in the red territory, down by just over 1 per cent. Why were Godavari Biorefineries' shares buzzing in trade? The buying on the counter came after the company announced in a latest exchange filing that its clinical-stage biotech division, Sathgen Therapeutics, was granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anticancer molecule. The patent covers a novel class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, as per the exchange filing. "Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr. Sangeeta Srivastava, executive director, Godavari Biorefineries. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," she added. Godavari Biorefineries already has an established presence on the global front. Its biotech division, Sathgen Therapeutics, is actively involved in the development of novel cancer and antiviral therapies. It is also worth mentioning that just earlier this month, the company was granted a patent in Europe for its novel anticancer molecule. About Godavari Biorefineries Godavari Biorefineries was originally incorporated as 'Godavari Investment and Finance Corporation Ltd.' in Mumbai on January 12, 1956. The name of the company was changed on November 10, 2006, as 'Godavari Biorefineries'. The company is involved in the manufacturing of ethanol-based chemicals in India and has one of the largest integrated bio-refineries in the country in terms of installed capacity.
Business Upturn
22-07-2025
- Business
- Business Upturn
Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer molecule
By Aditya Bhagchandani Published on July 22, 2025, 11:51 IST Godavari Biorefineries Ltd has announced that it has been granted a Chinese patent for its innovative anti-cancer molecule, marking a significant step forward in the development of treatments for cancer. The company disclosed the development through a press release to the stock exchanges on Tuesday, July 22, in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. The patented molecule represents a breakthrough in the field and is intended for use in cancer treatment, expanding the company's intellectual property portfolio in the life sciences sector. Godavari Biorefineries stated that this milestone strengthens its ongoing research initiatives and enhances its position in the global pharmaceutical and biotech space. Further details about the molecule and its planned development pathway are expected to be shared in subsequent announcements. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
07-07-2025
- Health
- Business Standard
Godavari Biorefineries' anti-cancer patent now validated in Spain and the UK
And as Unitary Patent covering multiple EU member states Godavari Biorefineries announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Godavari Biorefineries share price hits 5% upper circuit today; here's why
Godavari Biorefineries share price: Godavari Biorefineries share price was in demand on Friday, July 4, 2025, with the scrip hitting 5 per cent upper circuit at ₹258.60 per share. However, at 10:20 AM, Godavari Biorefineries share price was off highs, but continued to trade higher, up 1.60 per cent at ₹250.25 per share. In comparison, BSE Sensex was trading flat at 83,229.22 levels. Why did Godavari Biorefineries hit 5% upper circuit today? Godavari Biorefineries share price rose after the company announced that it has been granted a patent in Europe for its novel anticancer molecule. In an exchange filing, Godavari Biorefineries said, 'This is to inform you that the Company has been granted a patent in Europe for our novel anticancer molecule. This patent is now validated in Spain, the UK, and as a Unitary Patent.' The patent subject area is 'Anti-Cancer Research Segment.' The patent covers a very potent anticancer compound with proven efficacy on cancer and cancer stem cells, the company said. Godavari Biorefineries Q4 results Godavari Biorefineries reported its financial results for Q4 FY25, showcasing operational resilience despite a slight dip in revenue. The company posted consolidated revenue from operations of ₹579.5 crore, down from ₹615.2 crore in the same quarter last year. However, profitability remained robust, with Ebitda at ₹121.7 crore and a healthy margin of 21 per cent, marginally up from the 20.2 per cent Ebitda margin recorded in Q4FY24. Profit after tax (PAT) stood at ₹71.9 crore, reflecting a PAT margin of 12.4 per cent, higher than the 10.6 per cent in the previous year. On Q4 show, Samir Somaiya, CMD of Godavari Refineries said, 'FY25 was a defining year for Godavari Biorefineries, showcasing our agility, disciplined execution, and strategic progress. Our Bio-based Chemicals segment delivered over 2x growth in Ebitda, propelled by our shift toward high-value, sustainable solutions and enhanced operational efficiencies. We also achieved a record cane crushing of 24.65 lakh tonnes for sugar season 2024-25 at our Sameerwadi restoration of the ethanol blending programme using sugarcane juice enabled us to better utilise our ethanol capacity during the crushing season.' Somaiya added, 'Looking ahead, our 200 KLPD grain/maize distillery is progressing as planned and is expected to be commissioned in Q4 FY26. We are also exploring multi-feedstock options for greater flexibility, while undertaking debottlenecking and expansion initiatives focused on specialty products. FY25 has laid a solid foundation for future growth, and we remain committed to delivering value through innovation, sustainability, and disciplined growth.' About Godavari Biorefineries Godavari Biorefineries Ltd. is one of India's leading producers of ethanol and a pioneer in the manufacturing of ethanol-based chemicals. The company boasts a diversified product portfolio that includes bio-based chemicals, sugar, rectified spirits, ethanol, various grades of alcohol, and power. Notably, it is the only company in India with such an extensive range of bio-based products, including MPO, natural 1,3-butylene glycol, ethyl vinyl ether, and several other specialty chemicals.
